Thiazolidinediones: do harms outweigh benefits?
- PMID: 19073650
- PMCID: PMC2612067
- DOI: 10.1503/cmaj.081713
Thiazolidinediones: do harms outweigh benefits?
Comment in
-
Thiazolidinedione use and the risk of fractures.CMAJ. 2009 Apr 14;180(8):841. doi: 10.1503/cmaj.1090005. CMAJ. 2009. PMID: 19364797 Free PMC article. No abstract available.
Comment on
-
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10. CMAJ. 2009. PMID: 19073651 Free PMC article.
References
-
- Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18. - PubMed
-
- Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36. - PubMed
-
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. - PubMed
-
- Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical